X4 Pharmaceuticals and Norgine Team Up to Expand Immunotherapy Reach in Europe and Beyond

X4 Pharmaceuticals (Nasdaq: XFOR), a biotechnology company focused on developing innovative therapies for rare diseases of the immune system, has entered into an exclusive licensing and supply agreement with Norgine, a leading European specialist pharmaceutical company. The partnership aims to commercialize mavorixafor, a selective CXCR4 receptor antagonist, in Europe, Australia, and New Zealand following regulatory approvals. This strategic alliance will strengthen X4's financial stability, expand its global reach, and potentially transform the market dynamics for immunotherapy in these key territories.



Under the terms of the agreement, X4 will receive a €28.5 million upfront payment, which will bolster its balance sheet and provide non-dilutive funds as enrollment ramps up in the company's global Phase 3 clinical trial in chronic neutropenia. Additionally, X4 is eligible to receive up to €226 million in potential regulatory and commercial milestone payments, along with escalating double-digit royalties of up to the mid-twenties on any future net sales in the licensed territories. These financial incentives will contribute to X4's revenue and support its ongoing research and development efforts.

The partnership with Norgine will enable X4 to leverage Norgine's extensive infrastructure and successful commercialization track record in specialty pharmaceuticals across Europe, Australia, and New Zealand. This collaboration will expand X4's global reach and allow it to bring mavorixafor to a larger patient population in need of innovative therapies for rare immune disorders. Norgine's expertise in rare diseases and specialty markets will also benefit X4, as it can draw upon Norgine's knowledge and resources to better address the unmet needs of patients in these key strategic territories.

Mavorixafor, marketed in the U.S. as XOLREMDI®, is an oral, once-daily treatment for patients 12 years of age and older with WHIM syndrome, a rare primary immunodeficiency. X4 expects to announce shortly the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for mavorixafor in the treatment of WHIM syndrome, for which it has been granted Orphan Drug Designation by both the EMA and the U.S. Food and Drug Administration. X4 is also developing mavorixafor to treat chronic neutropenia (CN) and is currently conducting a global, pivotal Phase 3 clinical trial in certain CN disorders.

The partnership between X4 Pharmaceuticals and Norgine is a significant milestone for both companies, as it allows them to maximize the global potential of mavorixafor and expand access to patients in need. By combining X4's expertise in CXCR4 and immune system biology with Norgine's commercialization prowess and rare disease experience, the alliance has the potential to transform the market dynamics for immunotherapy in Europe, Australia, and New Zealand. As mavorixafor gains regulatory approvals and enters these key territories, it could capture a significant share of the market for WHIM syndrome treatments and potentially expand into chronic neutropenia, addressing unmet needs and generating revenue for both companies.

In conclusion, the partnership between X4 Pharmaceuticals and Norgine is a strategic move that strengthens X4's financial stability, expands its global reach, and has the potential to reshape the market dynamics for immunotherapy in Europe, Australia, and New Zealand. By combining their respective strengths and expertise, the two companies aim to maximize the global potential of mavorixafor and bring innovative therapies to patients in need of rare disease treatments.